FDA allows Houston cancer doctor to resume drug trial

Federal regulators have lifted a partial hold on a clinical trial performed by Stanislaw

The next generation of evidence-based medicine

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study - The Lancet Oncology

FDA gives controversial doc green light to restart work

FDA panel: Benefit of 'highly anticipated' lung cancer drug can't be interpreted reliably

Pancreatic Cancer: Dasatinib Trial Negative in Locally Advanced Pancreatic Cancer, Article

Here's who could be helped by new cancer drug — and when

FibroGen limited access to Duchenne muscular dystrophy drug after failed clinical trial. But mom says it works for her son. - San Francisco Business Times

New Survey Reveals Cancer Survivors' Attitudes to Care, Unmet Needs, Article

Feeling Like Death': Inside a Houston Hospital Bracing for a Virus Peak - The New York Times

Doctor claims to cure pediatric cancer, critics skeptical

FDA issues warning to controversial Houston cancer doctor

Luis Diaz Jr., MD - MSK Gastrointestinal Oncologist

Department of Labor and Food and Drug Administration Confirmations Hearing

Helping cancer patients navigate CAR T cell therapy